earnings
confidence high
sentiment positive
materiality 0.70
Tenax Therapeutics reports Q2 net loss of $3.6M, cash $9.4M; raised $100M
TENAX THERAPEUTICS, INC.
2025-Q2 EPS
reported -$4.65
vs consensus -$0.24
▼ miss
(-1799.5%)
- Net loss of $3.6M ($1.83/sh) vs loss of $1.1M ($4.00/sh) in Q2 2023.
- R&D expenses $2.3M, up from $0.2M due to Phase 3 LEVEL study costs.
- Cash and equivalents $9.4M at June 30; subsequent private placement raised $100M gross.
- Phase 3 LEVEL study enrolling with 39 investigative sites; patent granted for levosimendan in PH-HFpEF.
- G&A expenses $1.3M vs $1.0M in prior-year quarter.